Literature DB >> 8908703

Monoclonal antibodies in cancer therapy.

R Gruber1, E Holz, G Riethmüller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8908703     DOI： 10.1007/bf00820669

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  51 in total

Review 1.  Monoclonal antibody-based therapies of leukemia and lymphoma.

Authors:  M L Grossbard; O W Press; F R Appelbaum; I D Bernstein; L M Nadler
Journal:  Blood       Date:  1992-08-15       Impact factor: 22.113

Review 2.  The therapeutic use of monoclonal antibodies in colorectal carcinoma.

Authors:  H Mellstedt; J E Frödin; G Masucci; P Ragnhammar; J Fagerberg; A L Hjelm; J Shetye; P Wersäll; A Osterborg
Journal:  Semin Oncol       Date:  1991-10       Impact factor: 4.929

3.  Monoclonal anti-idiotypic antibody functionally mimics the human gastrointestinal carcinoma epitope GA733.

Authors:  H Maruyama; A Benden; W Li; J Zaloudik; T Koido; J L Taupin; B Acres; R Somasundaram; M Prewett; D Herlyn
Journal:  Int J Cancer       Date:  1996-02-08       Impact factor: 7.396

4.  Monoclonal IgG as antigens: reduction is an early intracellular event of their processing by antigen-presenting cells.

Authors:  L Santoro; A Reboul; I Kerblat; C Drouet; M G Colomb
Journal:  Int Immunol       Date:  1996-02       Impact factor: 4.823

Review 5.  Immunotoxins: magic bullets or misguided missiles?

Authors:  E S Vitetta; P E Thorpe; J W Uhr
Journal:  Immunol Today       Date:  1993-06

6.  Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.

Authors:  M Asano; A Yukita; T Matsumoto; S Kondo; H Suzuki
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

7.  Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced.

Authors:  P Ragnhammar; J Fagerberg; J E Frödin; A L Hjelm; C Lindemalm; I Magnusson; G Masucci; H Mellstedt
Journal:  Int J Cancer       Date:  1993-03-12       Impact factor: 7.396

8.  Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer.

Authors:  M N Saleh; M B Khazaeli; R H Wheeler; R P Bucy; T Liu; M P Everson; D H Munn; J Schlom; A F LoBuglio
Journal:  Cancer Res       Date:  1995-10-01       Impact factor: 12.701

9.  Presence on a human melanoma of multiple antigens recognized by autologous CTL.

Authors:  B Van den Eynde; P Hainaut; M Hérin; A Knuth; C Lemoine; P Weynants; P van der Bruggen; R Fauchet; T Boon
Journal:  Int J Cancer       Date:  1989-10-15       Impact factor: 7.396

10.  Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.

Authors:  P Ragnhammar; J Fagerberg; J E Frödin; P Wersäll; L O Hansson; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968
View more
  3 in total

1.  Ascitic complement system in ovarian cancer.

Authors:  L Bjørge; J Hakulinen; O K Vintermyr; H Jarva; T S Jensen; O E Iversen; S Meri
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

2.  Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines.

Authors:  N Prang; S Preithner; K Brischwein; P Göster; A Wöppel; J Müller; C Steiger; M Peters; P A Baeuerle; A J da Silva
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

Review 3.  Therapeutic applications of monoclonal antibodies.

Authors:  Mitchell Berger; Vidya Shankar; Abbas Vafai
Journal:  Am J Med Sci       Date:  2002-07       Impact factor: 2.378
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.